Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.

Huifeng Tang Hui ZhouJuying WeiHui LiuWenbin QianXiaohui Chen

Published in: Hematology (Amsterdam, Netherlands) (2019)

CD5+ DLBCL patients have the distinctive clinical and biological features, they should be provided with clinic individualized treatment and important pathways with therapeutic implications should be underscored.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
primary care
prognostic factors
patient reported outcomes